nodes	percent_of_prediction	percent_of_DWPC	metapath
Lomitapide—International normalised ratio abnormal—Sorafenib—liver cancer	0.114	0.198	CcSEcCtD
Lomitapide—ABCB1—Sorafenib—liver cancer	0.105	0.389	CbGbCtD
Lomitapide—ABCB1—Doxorubicin—liver cancer	0.0639	0.236	CbGbCtD
Lomitapide—CYP3A4—Sorafenib—liver cancer	0.0631	0.233	CbGbCtD
Lomitapide—CYP3A4—Doxorubicin—liver cancer	0.0383	0.141	CbGbCtD
Lomitapide—Abdominal tenderness—Sorafenib—liver cancer	0.0271	0.0473	CcSEcCtD
Lomitapide—Abdominal pain lower—Sorafenib—liver cancer	0.0215	0.0376	CcSEcCtD
Lomitapide—Blood potassium decreased—Sorafenib—liver cancer	0.018	0.0314	CcSEcCtD
Lomitapide—MTTP—Circadian rythm related genes—SIX3—liver cancer	0.00972	0.0622	CbGpPWpGaD
Lomitapide—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.00758	0.0132	CcSEcCtD
Lomitapide—Drug interaction—Sorafenib—liver cancer	0.00738	0.0129	CcSEcCtD
Lomitapide—Blood bilirubin increased—Sorafenib—liver cancer	0.00724	0.0126	CcSEcCtD
Lomitapide—CYP3A4—Felbamate Metabolism—CYP2E1—liver cancer	0.00709	0.0454	CbGpPWpGaD
Lomitapide—Rectal tenesmus—Epirubicin—liver cancer	0.00679	0.0118	CcSEcCtD
Lomitapide—Rectal tenesmus—Doxorubicin—liver cancer	0.00629	0.011	CcSEcCtD
Lomitapide—Prothrombin level increased—Epirubicin—liver cancer	0.00617	0.0108	CcSEcCtD
Lomitapide—MTTP—Lipoprotein metabolism—ALB—liver cancer	0.00588	0.0377	CbGpPWpGaD
Lomitapide—Prothrombin level increased—Doxorubicin—liver cancer	0.00571	0.00996	CcSEcCtD
Lomitapide—Proctalgia—Epirubicin—liver cancer	0.0054	0.00941	CcSEcCtD
Lomitapide—Proctalgia—Doxorubicin—liver cancer	0.00499	0.00871	CcSEcCtD
Lomitapide—Pain in extremity—Sorafenib—liver cancer	0.00497	0.00867	CcSEcCtD
Lomitapide—Anorectal discomfort—Epirubicin—liver cancer	0.00463	0.00807	CcSEcCtD
Lomitapide—Dehydration—Sorafenib—liver cancer	0.00462	0.00806	CcSEcCtD
Lomitapide—Dry skin—Sorafenib—liver cancer	0.00456	0.00795	CcSEcCtD
Lomitapide—Abdominal pain upper—Sorafenib—liver cancer	0.00454	0.00792	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00448	0.00781	CcSEcCtD
Lomitapide—Nasopharyngitis—Sorafenib—liver cancer	0.00445	0.00775	CcSEcCtD
Lomitapide—Gastritis—Sorafenib—liver cancer	0.0044	0.00767	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00438	0.00765	CcSEcCtD
Lomitapide—Anorectal discomfort—Doxorubicin—liver cancer	0.00428	0.00747	CcSEcCtD
Lomitapide—CYP3A4—Liver X Receptor Pathway—SCD—liver cancer	0.00426	0.0273	CbGpPWpGaD
Lomitapide—Transaminases increased—Epirubicin—liver cancer	0.00416	0.00726	CcSEcCtD
Lomitapide—Abdominal discomfort—Sorafenib—liver cancer	0.00412	0.00718	CcSEcCtD
Lomitapide—MTTP—Lipid and lipoprotein metabolism—ALB—liver cancer	0.00391	0.025	CbGpPWpGaD
Lomitapide—Weight decreased—Sorafenib—liver cancer	0.00389	0.00678	CcSEcCtD
Lomitapide—Transaminases increased—Doxorubicin—liver cancer	0.00385	0.00671	CcSEcCtD
Lomitapide—Infestation NOS—Sorafenib—liver cancer	0.00383	0.00668	CcSEcCtD
Lomitapide—Infestation—Sorafenib—liver cancer	0.00383	0.00668	CcSEcCtD
Lomitapide—ABCB1—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00381	0.0244	CbGpPWpGaD
Lomitapide—ABCB1—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00375	0.024	CbGpPWpGaD
Lomitapide—MTTP—Circadian rythm related genes—AHR—liver cancer	0.00369	0.0236	CbGpPWpGaD
Lomitapide—Haematemesis—Epirubicin—liver cancer	0.00364	0.00635	CcSEcCtD
Lomitapide—Hepatobiliary disease—Sorafenib—liver cancer	0.00362	0.00632	CcSEcCtD
Lomitapide—Hepatomegaly—Epirubicin—liver cancer	0.00358	0.00624	CcSEcCtD
Lomitapide—Blister—Epirubicin—liver cancer	0.00351	0.00612	CcSEcCtD
Lomitapide—Urinary tract disorder—Sorafenib—liver cancer	0.0034	0.00592	CcSEcCtD
Lomitapide—Connective tissue disorder—Sorafenib—liver cancer	0.00338	0.00589	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.00338	0.0216	CbGpPWpGaD
Lomitapide—Urethral disorder—Sorafenib—liver cancer	0.00337	0.00588	CcSEcCtD
Lomitapide—Haematemesis—Doxorubicin—liver cancer	0.00337	0.00588	CcSEcCtD
Lomitapide—Hepatomegaly—Doxorubicin—liver cancer	0.00331	0.00577	CcSEcCtD
Lomitapide—Rash erythematous—Epirubicin—liver cancer	0.0033	0.00576	CcSEcCtD
Lomitapide—Blister—Doxorubicin—liver cancer	0.00325	0.00567	CcSEcCtD
Lomitapide—Cardiac disorder—Sorafenib—liver cancer	0.00319	0.00557	CcSEcCtD
Lomitapide—Mediastinal disorder—Sorafenib—liver cancer	0.0031	0.00541	CcSEcCtD
Lomitapide—Rash erythematous—Doxorubicin—liver cancer	0.00306	0.00533	CcSEcCtD
Lomitapide—Malnutrition—Sorafenib—liver cancer	0.00299	0.00522	CcSEcCtD
Lomitapide—Muscle spasms—Sorafenib—liver cancer	0.00288	0.00502	CcSEcCtD
Lomitapide—Anaemia—Sorafenib—liver cancer	0.00277	0.00483	CcSEcCtD
Lomitapide—Blood bilirubin increased—Epirubicin—liver cancer	0.00268	0.00467	CcSEcCtD
Lomitapide—Gait disturbance—Epirubicin—liver cancer	0.00259	0.00452	CcSEcCtD
Lomitapide—Myalgia—Sorafenib—liver cancer	0.00255	0.00445	CcSEcCtD
Lomitapide—Arthralgia—Sorafenib—liver cancer	0.00255	0.00445	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00253	0.00441	CcSEcCtD
Lomitapide—Dry mouth—Sorafenib—liver cancer	0.00249	0.00435	CcSEcCtD
Lomitapide—Eructation—Epirubicin—liver cancer	0.00249	0.00434	CcSEcCtD
Lomitapide—Blood bilirubin increased—Doxorubicin—liver cancer	0.00248	0.00432	CcSEcCtD
Lomitapide—Infection—Sorafenib—liver cancer	0.00243	0.00423	CcSEcCtD
Lomitapide—Gait disturbance—Doxorubicin—liver cancer	0.0024	0.00418	CcSEcCtD
Lomitapide—Nervous system disorder—Sorafenib—liver cancer	0.0024	0.00418	CcSEcCtD
Lomitapide—Skin disorder—Sorafenib—liver cancer	0.00237	0.00414	CcSEcCtD
Lomitapide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00235	0.015	CbGpPWpGaD
Lomitapide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00231	0.0148	CbGpPWpGaD
Lomitapide—Eructation—Doxorubicin—liver cancer	0.0023	0.00401	CcSEcCtD
Lomitapide—Ecchymosis—Epirubicin—liver cancer	0.00229	0.00399	CcSEcCtD
Lomitapide—ABCB1—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00226	0.0145	CbGpPWpGaD
Lomitapide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00223	0.00388	CcSEcCtD
Lomitapide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00219	0.014	CbGpPWpGaD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00218	0.0139	CbGpPWpGaD
Lomitapide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00215	0.0138	CbGpPWpGaD
Lomitapide—Dyspepsia—Sorafenib—liver cancer	0.00215	0.00375	CcSEcCtD
Lomitapide—CYP3A4—Farnesoid X Receptor  Pathway—NR1H4—liver cancer	0.00215	0.0138	CbGpPWpGaD
Lomitapide—Decreased appetite—Sorafenib—liver cancer	0.00212	0.0037	CcSEcCtD
Lomitapide—Ecchymosis—Doxorubicin—liver cancer	0.00212	0.00369	CcSEcCtD
Lomitapide—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00211	0.00368	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Sorafenib—liver cancer	0.00211	0.00368	CcSEcCtD
Lomitapide—Fatigue—Sorafenib—liver cancer	0.00211	0.00367	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.0021	0.0134	CbGpPWpGaD
Lomitapide—Constipation—Sorafenib—liver cancer	0.00209	0.00364	CcSEcCtD
Lomitapide—ABCB1—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00201	0.0129	CbGpPWpGaD
Lomitapide—Gastrointestinal pain—Sorafenib—liver cancer	0.002	0.00348	CcSEcCtD
Lomitapide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.00197	0.0126	CbGpPWpGaD
Lomitapide—Increased appetite—Epirubicin—liver cancer	0.00196	0.00341	CcSEcCtD
Lomitapide—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00195	0.00341	CcSEcCtD
Lomitapide—Abdominal pain—Sorafenib—liver cancer	0.00193	0.00337	CcSEcCtD
Lomitapide—Body temperature increased—Sorafenib—liver cancer	0.00193	0.00337	CcSEcCtD
Lomitapide—Dermatitis bullous—Epirubicin—liver cancer	0.00192	0.00335	CcSEcCtD
Lomitapide—CYP3A4—Estrogen metabolism—GSTA1—liver cancer	0.0019	0.0121	CbGpPWpGaD
Lomitapide—Pain in extremity—Epirubicin—liver cancer	0.00184	0.0032	CcSEcCtD
Lomitapide—Increased appetite—Doxorubicin—liver cancer	0.00181	0.00316	CcSEcCtD
Lomitapide—Migraine—Epirubicin—liver cancer	0.00181	0.00315	CcSEcCtD
Lomitapide—Dermatitis bullous—Doxorubicin—liver cancer	0.00178	0.0031	CcSEcCtD
Lomitapide—Asthenia—Sorafenib—liver cancer	0.00175	0.00306	CcSEcCtD
Lomitapide—MTTP—Circadian rythm related genes—PPARA—liver cancer	0.00173	0.0111	CbGpPWpGaD
Lomitapide—Dehydration—Epirubicin—liver cancer	0.00171	0.00298	CcSEcCtD
Lomitapide—Pain in extremity—Doxorubicin—liver cancer	0.0017	0.00296	CcSEcCtD
Lomitapide—Liver function test abnormal—Epirubicin—liver cancer	0.0017	0.00296	CcSEcCtD
Lomitapide—Dry skin—Epirubicin—liver cancer	0.00168	0.00294	CcSEcCtD
Lomitapide—Abdominal pain upper—Epirubicin—liver cancer	0.00168	0.00293	CcSEcCtD
Lomitapide—Migraine—Doxorubicin—liver cancer	0.00167	0.00292	CcSEcCtD
Lomitapide—Diarrhoea—Sorafenib—liver cancer	0.00167	0.00292	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00165	0.00289	CcSEcCtD
Lomitapide—Nasopharyngitis—Epirubicin—liver cancer	0.00164	0.00287	CcSEcCtD
Lomitapide—Gastritis—Epirubicin—liver cancer	0.00163	0.00284	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00162	0.00283	CcSEcCtD
Lomitapide—Dizziness—Sorafenib—liver cancer	0.00162	0.00282	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.00161	0.0103	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—UGDH—liver cancer	0.0016	0.0103	CbGpPWpGaD
Lomitapide—Abdominal distension—Epirubicin—liver cancer	0.0016	0.00279	CcSEcCtD
Lomitapide—Influenza—Epirubicin—liver cancer	0.00159	0.00277	CcSEcCtD
Lomitapide—Dehydration—Doxorubicin—liver cancer	0.00158	0.00276	CcSEcCtD
Lomitapide—Liver function test abnormal—Doxorubicin—liver cancer	0.00157	0.00274	CcSEcCtD
Lomitapide—Dry skin—Doxorubicin—liver cancer	0.00156	0.00272	CcSEcCtD
Lomitapide—Vomiting—Sorafenib—liver cancer	0.00155	0.00271	CcSEcCtD
Lomitapide—Abdominal pain upper—Doxorubicin—liver cancer	0.00155	0.00271	CcSEcCtD
Lomitapide—Angina pectoris—Epirubicin—liver cancer	0.00155	0.0027	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00153	0.00267	CcSEcCtD
Lomitapide—Headache—Sorafenib—liver cancer	0.00153	0.00267	CcSEcCtD
Lomitapide—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.00153	0.00979	CbGpPWpGaD
Lomitapide—Nasopharyngitis—Doxorubicin—liver cancer	0.00152	0.00265	CcSEcCtD
Lomitapide—MTTP—Metabolism—EPT1—liver cancer	0.0015	0.00964	CbGpPWpGaD
Lomitapide—Gastritis—Doxorubicin—liver cancer	0.0015	0.00262	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.0015	0.00261	CcSEcCtD
Lomitapide—Abdominal distension—Doxorubicin—liver cancer	0.00148	0.00258	CcSEcCtD
Lomitapide—Influenza—Doxorubicin—liver cancer	0.00147	0.00256	CcSEcCtD
Lomitapide—Nausea—Sorafenib—liver cancer	0.00145	0.00253	CcSEcCtD
Lomitapide—Weight decreased—Epirubicin—liver cancer	0.00144	0.00251	CcSEcCtD
Lomitapide—Angina pectoris—Doxorubicin—liver cancer	0.00143	0.0025	CcSEcCtD
Lomitapide—MTTP—Circadian rythm related genes—PPARG—liver cancer	0.00143	0.00915	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—TAT—liver cancer	0.00143	0.00914	CbGpPWpGaD
Lomitapide—Infestation NOS—Epirubicin—liver cancer	0.00142	0.00247	CcSEcCtD
Lomitapide—Infestation—Epirubicin—liver cancer	0.00142	0.00247	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.0014	0.00899	CbGpPWpGaD
Lomitapide—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00139	0.00891	CbGpPWpGaD
Lomitapide—Haematuria—Epirubicin—liver cancer	0.00135	0.00235	CcSEcCtD
Lomitapide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00135	0.00863	CbGpPWpGaD
Lomitapide—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00134	0.0086	CbGpPWpGaD
Lomitapide—Hepatobiliary disease—Epirubicin—liver cancer	0.00134	0.00234	CcSEcCtD
Lomitapide—Weight decreased—Doxorubicin—liver cancer	0.00133	0.00232	CcSEcCtD
Lomitapide—Sinusitis—Epirubicin—liver cancer	0.00133	0.00232	CcSEcCtD
Lomitapide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00133	0.00849	CbGpPWpGaD
Lomitapide—Infestation NOS—Doxorubicin—liver cancer	0.00131	0.00228	CcSEcCtD
Lomitapide—Infestation—Doxorubicin—liver cancer	0.00131	0.00228	CcSEcCtD
Lomitapide—MTTP—Circadian rythm related genes—SERPINE1—liver cancer	0.00129	0.00824	CbGpPWpGaD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—NDRG1—liver cancer	0.00127	0.0081	CbGpPWpGaD
Lomitapide—Urinary tract disorder—Epirubicin—liver cancer	0.00126	0.00219	CcSEcCtD
Lomitapide—Haematuria—Doxorubicin—liver cancer	0.00125	0.00218	CcSEcCtD
Lomitapide—Connective tissue disorder—Epirubicin—liver cancer	0.00125	0.00218	CcSEcCtD
Lomitapide—Urethral disorder—Epirubicin—liver cancer	0.00125	0.00217	CcSEcCtD
Lomitapide—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00124	0.00794	CbGpPWpGaD
Lomitapide—Hepatobiliary disease—Doxorubicin—liver cancer	0.00124	0.00216	CcSEcCtD
Lomitapide—Sinusitis—Doxorubicin—liver cancer	0.00123	0.00214	CcSEcCtD
Lomitapide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.00119	0.00763	CbGpPWpGaD
Lomitapide—Eye disorder—Epirubicin—liver cancer	0.00119	0.00207	CcSEcCtD
Lomitapide—Cardiac disorder—Epirubicin—liver cancer	0.00118	0.00206	CcSEcCtD
Lomitapide—Urinary tract disorder—Doxorubicin—liver cancer	0.00116	0.00203	CcSEcCtD
Lomitapide—Connective tissue disorder—Doxorubicin—liver cancer	0.00116	0.00202	CcSEcCtD
Lomitapide—Urethral disorder—Doxorubicin—liver cancer	0.00115	0.00201	CcSEcCtD
Lomitapide—Mediastinal disorder—Epirubicin—liver cancer	0.00115	0.002	CcSEcCtD
Lomitapide—Chills—Epirubicin—liver cancer	0.00114	0.00199	CcSEcCtD
Lomitapide—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00112	0.00719	CbGpPWpGaD
Lomitapide—Malnutrition—Epirubicin—liver cancer	0.00111	0.00193	CcSEcCtD
Lomitapide—Eye disorder—Doxorubicin—liver cancer	0.0011	0.00192	CcSEcCtD
Lomitapide—Cardiac disorder—Doxorubicin—liver cancer	0.00109	0.0019	CcSEcCtD
Lomitapide—Flatulence—Epirubicin—liver cancer	0.00109	0.0019	CcSEcCtD
Lomitapide—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.00108	0.00692	CbGpPWpGaD
Lomitapide—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.00107	0.00688	CbGpPWpGaD
Lomitapide—Back pain—Epirubicin—liver cancer	0.00107	0.00187	CcSEcCtD
Lomitapide—Muscle spasms—Epirubicin—liver cancer	0.00106	0.00186	CcSEcCtD
Lomitapide—Mediastinal disorder—Doxorubicin—liver cancer	0.00106	0.00185	CcSEcCtD
Lomitapide—Chills—Doxorubicin—liver cancer	0.00106	0.00184	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.00105	0.00673	CbGpPWpGaD
Lomitapide—Ill-defined disorder—Epirubicin—liver cancer	0.00103	0.00179	CcSEcCtD
Lomitapide—Malnutrition—Doxorubicin—liver cancer	0.00102	0.00179	CcSEcCtD
Lomitapide—Anaemia—Epirubicin—liver cancer	0.00102	0.00178	CcSEcCtD
Lomitapide—MTTP—Circadian rythm related genes—JUN—liver cancer	0.00101	0.00649	CbGpPWpGaD
Lomitapide—Flatulence—Doxorubicin—liver cancer	0.00101	0.00176	CcSEcCtD
Lomitapide—ABCB1—Allograft Rejection—IL12A—liver cancer	0.001	0.00642	CbGpPWpGaD
Lomitapide—Malaise—Epirubicin—liver cancer	0.000998	0.00174	CcSEcCtD
Lomitapide—Vertigo—Epirubicin—liver cancer	0.000994	0.00173	CcSEcCtD
Lomitapide—Back pain—Doxorubicin—liver cancer	0.00099	0.00173	CcSEcCtD
Lomitapide—Muscle spasms—Doxorubicin—liver cancer	0.000984	0.00172	CcSEcCtD
Lomitapide—Palpitations—Epirubicin—liver cancer	0.000978	0.00171	CcSEcCtD
Lomitapide—MTTP—Metabolism—CPT1B—liver cancer	0.00097	0.00621	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—GLUL—liver cancer	0.00097	0.00621	CbGpPWpGaD
Lomitapide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000964	0.00618	CbGpPWpGaD
Lomitapide—MTTP—Circadian rythm related genes—MAPK8—liver cancer	0.000959	0.00614	CbGpPWpGaD
Lomitapide—Ill-defined disorder—Doxorubicin—liver cancer	0.00095	0.00166	CcSEcCtD
Lomitapide—Anaemia—Doxorubicin—liver cancer	0.000946	0.00165	CcSEcCtD
Lomitapide—Myalgia—Epirubicin—liver cancer	0.000942	0.00164	CcSEcCtD
Lomitapide—Arthralgia—Epirubicin—liver cancer	0.000942	0.00164	CcSEcCtD
Lomitapide—Chest pain—Epirubicin—liver cancer	0.000942	0.00164	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000935	0.00163	CcSEcCtD
Lomitapide—MTTP—Metabolism—NR1H4—liver cancer	0.000935	0.00599	CbGpPWpGaD
Lomitapide—Discomfort—Epirubicin—liver cancer	0.000931	0.00162	CcSEcCtD
Lomitapide—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.000926	0.00593	CbGpPWpGaD
Lomitapide—Malaise—Doxorubicin—liver cancer	0.000923	0.00161	CcSEcCtD
Lomitapide—Dry mouth—Epirubicin—liver cancer	0.000921	0.00161	CcSEcCtD
Lomitapide—Vertigo—Doxorubicin—liver cancer	0.00092	0.0016	CcSEcCtD
Lomitapide—MTTP—Metabolism—GSTA3—liver cancer	0.000919	0.00589	CbGpPWpGaD
Lomitapide—Palpitations—Doxorubicin—liver cancer	0.000905	0.00158	CcSEcCtD
Lomitapide—Infection—Epirubicin—liver cancer	0.000897	0.00156	CcSEcCtD
Lomitapide—Nervous system disorder—Epirubicin—liver cancer	0.000886	0.00154	CcSEcCtD
Lomitapide—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.000878	0.00562	CbGpPWpGaD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—HNF4A—liver cancer	0.000877	0.00562	CbGpPWpGaD
Lomitapide—Skin disorder—Epirubicin—liver cancer	0.000877	0.00153	CcSEcCtD
Lomitapide—Hyperhidrosis—Epirubicin—liver cancer	0.000873	0.00152	CcSEcCtD
Lomitapide—Arthralgia—Doxorubicin—liver cancer	0.000872	0.00152	CcSEcCtD
Lomitapide—Myalgia—Doxorubicin—liver cancer	0.000872	0.00152	CcSEcCtD
Lomitapide—Chest pain—Doxorubicin—liver cancer	0.000872	0.00152	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000866	0.00151	CcSEcCtD
Lomitapide—Discomfort—Doxorubicin—liver cancer	0.000861	0.0015	CcSEcCtD
Lomitapide—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000856	0.00548	CbGpPWpGaD
Lomitapide—Dry mouth—Doxorubicin—liver cancer	0.000852	0.00149	CcSEcCtD
Lomitapide—MTTP—Metabolism—GSTA4—liver cancer	0.000841	0.00538	CbGpPWpGaD
Lomitapide—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.000841	0.00538	CbGpPWpGaD
Lomitapide—Infection—Doxorubicin—liver cancer	0.00083	0.00145	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000823	0.00143	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000822	0.00526	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—GSTA2—liver cancer	0.000819	0.00525	CbGpPWpGaD
Lomitapide—Nervous system disorder—Doxorubicin—liver cancer	0.000819	0.00143	CcSEcCtD
Lomitapide—Skin disorder—Doxorubicin—liver cancer	0.000812	0.00142	CcSEcCtD
Lomitapide—Paraesthesia—Epirubicin—liver cancer	0.000811	0.00141	CcSEcCtD
Lomitapide—Hyperhidrosis—Doxorubicin—liver cancer	0.000808	0.00141	CcSEcCtD
Lomitapide—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.000807	0.00517	CbGpPWpGaD
Lomitapide—Somnolence—Epirubicin—liver cancer	0.000803	0.0014	CcSEcCtD
Lomitapide—Dyspepsia—Epirubicin—liver cancer	0.000795	0.00139	CcSEcCtD
Lomitapide—MTTP—Metabolism—GSTA1—liver cancer	0.000791	0.00506	CbGpPWpGaD
Lomitapide—Decreased appetite—Epirubicin—liver cancer	0.000785	0.00137	CcSEcCtD
Lomitapide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000783	0.00502	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—NAT2—liver cancer	0.000782	0.00501	CbGpPWpGaD
Lomitapide—Gastrointestinal disorder—Epirubicin—liver cancer	0.00078	0.00136	CcSEcCtD
Lomitapide—Fatigue—Epirubicin—liver cancer	0.000778	0.00136	CcSEcCtD
Lomitapide—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.000776	0.00497	CbGpPWpGaD
Lomitapide—Constipation—Epirubicin—liver cancer	0.000772	0.00135	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000761	0.00133	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000752	0.00481	CbGpPWpGaD
Lomitapide—Paraesthesia—Doxorubicin—liver cancer	0.00075	0.00131	CcSEcCtD
Lomitapide—MTTP—Metabolism—ALDOB—liver cancer	0.000749	0.0048	CbGpPWpGaD
Lomitapide—Feeling abnormal—Epirubicin—liver cancer	0.000744	0.0013	CcSEcCtD
Lomitapide—Somnolence—Doxorubicin—liver cancer	0.000743	0.0013	CcSEcCtD
Lomitapide—Gastrointestinal pain—Epirubicin—liver cancer	0.000738	0.00129	CcSEcCtD
Lomitapide—Dyspepsia—Doxorubicin—liver cancer	0.000735	0.00128	CcSEcCtD
Lomitapide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000734	0.0047	CbGpPWpGaD
Lomitapide—Decreased appetite—Doxorubicin—liver cancer	0.000726	0.00127	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000721	0.00126	CcSEcCtD
Lomitapide—Fatigue—Doxorubicin—liver cancer	0.00072	0.00126	CcSEcCtD
Lomitapide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—liver cancer	0.000717	0.00459	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—CRABP1—liver cancer	0.000715	0.00458	CbGpPWpGaD
Lomitapide—Constipation—Doxorubicin—liver cancer	0.000714	0.00125	CcSEcCtD
Lomitapide—Body temperature increased—Epirubicin—liver cancer	0.000714	0.00124	CcSEcCtD
Lomitapide—Abdominal pain—Epirubicin—liver cancer	0.000714	0.00124	CcSEcCtD
Lomitapide—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000694	0.00444	CbGpPWpGaD
Lomitapide—Feeling abnormal—Doxorubicin—liver cancer	0.000688	0.0012	CcSEcCtD
Lomitapide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000683	0.00119	CcSEcCtD
Lomitapide—MTTP—Circadian rythm related genes—TP53—liver cancer	0.000669	0.00428	CbGpPWpGaD
Lomitapide—Abdominal pain—Doxorubicin—liver cancer	0.00066	0.00115	CcSEcCtD
Lomitapide—Body temperature increased—Doxorubicin—liver cancer	0.00066	0.00115	CcSEcCtD
Lomitapide—Asthenia—Epirubicin—liver cancer	0.000648	0.00113	CcSEcCtD
Lomitapide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000647	0.00415	CbGpPWpGaD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000644	0.00412	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—UGDH—liver cancer	0.000631	0.00404	CbGpPWpGaD
Lomitapide—ABCB1—Allograft Rejection—IL12B—liver cancer	0.000629	0.00403	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—HPGDS—liver cancer	0.000625	0.004	CbGpPWpGaD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.000621	0.00398	CbGpPWpGaD
Lomitapide—Diarrhoea—Epirubicin—liver cancer	0.000618	0.00108	CcSEcCtD
Lomitapide—MTTP—Circadian rythm related genes—IL6—liver cancer	0.000612	0.00392	CbGpPWpGaD
Lomitapide—Asthenia—Doxorubicin—liver cancer	0.000599	0.00105	CcSEcCtD
Lomitapide—Dizziness—Epirubicin—liver cancer	0.000597	0.00104	CcSEcCtD
Lomitapide—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000577	0.00369	CbGpPWpGaD
Lomitapide—Vomiting—Epirubicin—liver cancer	0.000574	0.001	CcSEcCtD
Lomitapide—Diarrhoea—Doxorubicin—liver cancer	0.000572	0.000997	CcSEcCtD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—HMOX1—liver cancer	0.00057	0.00365	CbGpPWpGaD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000566	0.00362	CbGpPWpGaD
Lomitapide—Headache—Epirubicin—liver cancer	0.000566	0.000987	CcSEcCtD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000559	0.00358	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PSMA4—liver cancer	0.000557	0.00357	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PSMD10—liver cancer	0.000557	0.00357	CbGpPWpGaD
Lomitapide—Dizziness—Doxorubicin—liver cancer	0.000552	0.000964	CcSEcCtD
Lomitapide—MTTP—Metabolism—GOT2—liver cancer	0.000542	0.00347	CbGpPWpGaD
Lomitapide—Nausea—Epirubicin—liver cancer	0.000536	0.000935	CcSEcCtD
Lomitapide—Vomiting—Doxorubicin—liver cancer	0.000531	0.000927	CcSEcCtD
Lomitapide—Headache—Doxorubicin—liver cancer	0.000523	0.000913	CcSEcCtD
Lomitapide—MTTP—Metabolism—CYP2E1—liver cancer	0.000509	0.00326	CbGpPWpGaD
Lomitapide—Nausea—Doxorubicin—liver cancer	0.000496	0.000866	CcSEcCtD
Lomitapide—ABCB1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000493	0.00316	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000493	0.00316	CbGpPWpGaD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.000493	0.00316	CbGpPWpGaD
Lomitapide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000483	0.00309	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.000482	0.00309	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—CYCS—liver cancer	0.000477	0.00305	CbGpPWpGaD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—TERT—liver cancer	0.000468	0.003	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—GOT1—liver cancer	0.000468	0.003	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—GGT1—liver cancer	0.000468	0.003	CbGpPWpGaD
Lomitapide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000466	0.00299	CbGpPWpGaD
Lomitapide—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.00046	0.00295	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—GSTP1—liver cancer	0.00042	0.00269	CbGpPWpGaD
Lomitapide—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000414	0.00265	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—HMOX1—liver cancer	0.000414	0.00265	CbGpPWpGaD
Lomitapide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000399	0.00255	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—GSTM1—liver cancer	0.000386	0.00247	CbGpPWpGaD
Lomitapide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000378	0.00242	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.000375	0.0024	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000369	0.00236	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.000368	0.00235	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—CYP1A1—liver cancer	0.000366	0.00234	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000362	0.00232	CbGpPWpGaD
Lomitapide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—liver cancer	0.00036	0.00231	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000357	0.00229	CbGpPWpGaD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—liver cancer	0.000343	0.0022	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—MTHFR—liver cancer	0.000341	0.00218	CbGpPWpGaD
Lomitapide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000335	0.00215	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PPARA—liver cancer	0.000335	0.00214	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000331	0.00212	CbGpPWpGaD
Lomitapide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000331	0.00212	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000327	0.00209	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000323	0.00207	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000312	0.002	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000308	0.00197	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000304	0.00195	CbGpPWpGaD
Lomitapide—MTTP—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	0.000301	0.00193	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PIK3CG—liver cancer	0.000287	0.00184	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PPARG—liver cancer	0.000277	0.00177	CbGpPWpGaD
Lomitapide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	0.000276	0.00176	CbGpPWpGaD
Lomitapide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000272	0.00174	CbGpPWpGaD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—JUN—liver cancer	0.00027	0.00173	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000258	0.00165	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000253	0.00162	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PIK3CD—liver cancer	0.000252	0.00161	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—ALB—liver cancer	0.000249	0.00159	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000246	0.00158	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000242	0.00155	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000241	0.00154	CbGpPWpGaD
Lomitapide—ABCB1—Allograft Rejection—CASP3—liver cancer	0.000241	0.00154	CbGpPWpGaD
Lomitapide—ABCB1—Allograft Rejection—IL2—liver cancer	0.000241	0.00154	CbGpPWpGaD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—liver cancer	0.000236	0.00151	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000231	0.00148	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000231	0.00148	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PIK3CB—liver cancer	0.00022	0.00141	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000218	0.0014	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000207	0.00133	CbGpPWpGaD
Lomitapide—ABCB1—Allograft Rejection—VEGFA—liver cancer	0.000204	0.00131	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000201	0.00129	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000198	0.00127	CbGpPWpGaD
Lomitapide—ABCB1—Allograft Rejection—TGFB1—liver cancer	0.000188	0.0012	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000184	0.00118	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000182	0.00116	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000178	0.00114	CbGpPWpGaD
Lomitapide—ABCB1—Allograft Rejection—TNF—liver cancer	0.000175	0.00112	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—UGDH—liver cancer	0.000175	0.00112	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000169	0.00108	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000166	0.00106	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—EPT1—liver cancer	0.000165	0.00105	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000163	0.00105	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—TAT—liver cancer	0.000156	0.001	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000152	0.000974	CbGpPWpGaD
Lomitapide—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	0.000151	0.000964	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.00015	0.000961	CbGpPWpGaD
Lomitapide—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000144	0.000924	CbGpPWpGaD
Lomitapide—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000142	0.000911	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—PIK3CA—liver cancer	0.000134	0.000858	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000132	0.000848	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000121	0.000777	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000119	0.000761	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000116	0.000741	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000115	0.000739	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000115	0.000734	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000112	0.000717	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	0.000111	0.000713	CbGpPWpGaD
Lomitapide—MTTP—Metabolism—AKT1—liver cancer	0.000109	0.000701	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000109	0.0007	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—UGDH—liver cancer	0.000108	0.000691	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GLUL—liver cancer	0.000106	0.000679	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—CPT1B—liver cancer	0.000106	0.000679	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—NR1H4—liver cancer	0.000102	0.000655	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—EPT1—liver cancer	0.000101	0.00065	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000101	0.000646	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GSTA3—liver cancer	0.000101	0.000644	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	9.68e-05	0.00062	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—TAT—liver cancer	9.62e-05	0.000616	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	9.28e-05	0.000594	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	9.26e-05	0.000593	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GSTA4—liver cancer	9.2e-05	0.000589	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GSTA2—liver cancer	8.96e-05	0.000574	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GSTA1—liver cancer	8.65e-05	0.000554	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	8.64e-05	0.000554	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	8.57e-05	0.000549	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—NAT2—liver cancer	8.55e-05	0.000548	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—ALDOB—liver cancer	8.2e-05	0.000525	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	7.88e-05	0.000504	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—CRABP1—liver cancer	7.82e-05	0.000501	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	7.82e-05	0.000501	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	7.62e-05	0.000488	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—HPGDS—liver cancer	6.84e-05	0.000438	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—CPT1B—liver cancer	6.54e-05	0.000419	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GLUL—liver cancer	6.54e-05	0.000419	CbGpPWpGaD
Lomitapide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	6.44e-05	0.000412	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—NR1H4—liver cancer	6.3e-05	0.000404	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GSTA3—liver cancer	6.2e-05	0.000397	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PSMD10—liver cancer	6.09e-05	0.00039	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PSMA4—liver cancer	6.09e-05	0.00039	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GOT2—liver cancer	5.93e-05	0.00038	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	5.81e-05	0.000372	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GSTA4—liver cancer	5.67e-05	0.000363	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—CYP2E1—liver cancer	5.57e-05	0.000357	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GSTA2—liver cancer	5.52e-05	0.000354	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GSTA1—liver cancer	5.33e-05	0.000341	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—NAT2—liver cancer	5.27e-05	0.000337	CbGpPWpGaD
Lomitapide—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	5.26e-05	0.000337	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—CYCS—liver cancer	5.21e-05	0.000334	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GOT1—liver cancer	5.12e-05	0.000328	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GGT1—liver cancer	5.12e-05	0.000328	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—ALDOB—liver cancer	5.05e-05	0.000323	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—CRABP1—liver cancer	4.82e-05	0.000309	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GSTP1—liver cancer	4.6e-05	0.000294	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—HMOX1—liver cancer	4.53e-05	0.00029	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—GSTM1—liver cancer	4.22e-05	0.00027	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—HPGDS—liver cancer	4.21e-05	0.00027	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—CYP1A1—liver cancer	4e-05	0.000256	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PSMA4—liver cancer	3.75e-05	0.00024	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PSMD10—liver cancer	3.75e-05	0.00024	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—MTHFR—liver cancer	3.73e-05	0.000239	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PPARA—liver cancer	3.66e-05	0.000235	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GOT2—liver cancer	3.65e-05	0.000234	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—CYP2E1—liver cancer	3.43e-05	0.00022	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—CYCS—liver cancer	3.21e-05	0.000206	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GGT1—liver cancer	3.15e-05	0.000202	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GOT1—liver cancer	3.15e-05	0.000202	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PIK3CG—liver cancer	3.14e-05	0.000201	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PPARG—liver cancer	3.03e-05	0.000194	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GSTP1—liver cancer	2.83e-05	0.000181	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—HMOX1—liver cancer	2.79e-05	0.000179	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PIK3CD—liver cancer	2.76e-05	0.000177	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—ALB—liver cancer	2.72e-05	0.000174	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—GSTM1—liver cancer	2.6e-05	0.000167	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—CYP1A1—liver cancer	2.47e-05	0.000158	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PIK3CB—liver cancer	2.4e-05	0.000154	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—MTHFR—liver cancer	2.3e-05	0.000147	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PPARA—liver cancer	2.26e-05	0.000144	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PIK3CG—liver cancer	1.93e-05	0.000124	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PPARG—liver cancer	1.87e-05	0.000119	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PIK3CD—liver cancer	1.7e-05	0.000109	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—ALB—liver cancer	1.68e-05	0.000107	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PIK3CB—liver cancer	1.48e-05	9.48e-05	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—PIK3CA—liver cancer	1.47e-05	9.38e-05	CbGpPWpGaD
Lomitapide—ABCB1—Metabolism—AKT1—liver cancer	1.2e-05	7.66e-05	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—PIK3CA—liver cancer	9.03e-06	5.78e-05	CbGpPWpGaD
Lomitapide—CYP3A4—Metabolism—AKT1—liver cancer	7.37e-06	4.72e-05	CbGpPWpGaD
